Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking less necessary.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
It’s just another earnings week in the life of pharmaceutical CEOs, with blockbuster expectations running up against cruel reality.
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
TD Bank was fined more than $3 billion by regulators in October in what’s arguably the biggest banking scandal of the year.
Europe’s bank M&A scene has been noticeably stagnant for a while, but that could all be about to change next year.
The Fed’s September rate cut turbo-charged the stock market, but can the market keep up its bull run for 2025?